Zepbound(tirzepatide) for chronic weight management (weight reduction and maintenance) was studied in 2 randomized, placebo-controlled, 72-week long, studies (SURMOUNT-1 and SURMOUNT-2) in over 3,400 adults with obesity or excess weight (overweight) and at least one weight-related condition. ...
The FDA is evaluating the new diabetes drug Mounjaro as an obesity treatment, and early results show it takes the benefits of Ozempic up a notch. Here’s how they compare.